In the Maelstrom: Managing Urgent National Safety Data Joyce A. Generali, RPh, MS, FASHP p I n mid-September 2012, the Tennessee Department of Health was notified of a patient with cultureconfirmed Asergillus fumigatus meningitis that was possibly associated with the administration of an epidural steroid injection, which was later identified as preservative-free methylprednisolone acetate (MPA) compounded at New England Compounding Center (NECC). By the end of September, an ongoing multistate investigation by state and local health departments in collaboration with the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) had identified several more infectious cases linked to the injectable product. NECC indicated that approximately 17,500 vials of MPA had been distributed to 75 facilities in 23 states. 1 An initial national recall of 3 MPA lots occurred in late September. The recall was later expanded to all lots of MPA, and then further expanded (October 6) to include all remaining NECC products. 2, 3 In its entirety, the list of recalled drug products was vast (approximately 70 pages) and varied. Based on information at the time, the FDA advised health care practitioners to inform patients who had received cardioplegic solutions or an NECC injectable product (including ophthalmic injectables) about symptoms of possible infection. In addition to the formal announcements provided by the CDC and FDA, this event was widely publicized in various media forums. In fact, the Boston Globe published the initial 3 recalled MPA lot numbers on October 3. 4 At the time this editorial is being drafted, information is being released daily that has an impact on the methods used both to ensure medication safety and to communicate urgent safety information to health care professionals and patients. By the time this editorial is published, we will know much more about the long-term implications of this unfortunate scenario and plans for improvement will be underway. But today, in the maelstrom of changing information, there are numerous issues still at hand. At the forefront is patient care. The mobilization of investigative teams, the collaboration between federal and state agencies, and the work of dedicated individuals in identifying and caring for affected patients should be recognized. Dissemination of information in a timely manner becomes a balancing act in the midst of an epidemic. As health care professionals, we are most comfortable with evidence-based data, and yet, in a scenario such as this, patient care decisions must be made with less information at hand. The FDA and CDC are providing updates on a daily basis, ranging from diagnosis and treatment to templates for patient notification. 1, 2 It has been noted that care of the affected patients will be prolonged and the legacy of this event will be long-lasting. Much of this information re-enforces the importance of surveillance in the health community regarding medication safety and the professional responsibility that includes reporting of adverse events associated with medications.
There has already been much discussion about the role of compounding pharmacies, their evolution of practice, their relationship to drug shortages, and the current regulation and monitoring of these sites. More dialogue is needed regarding the complex nature of medication preparation. In the aftermath of tragedy, there is opportunity for examination with the intent to improve the process and prevent future risk. A forum regarding safety in the medication preparation process will be essential, including but not limited to input from professional pharmacy organizations and groups, pharmaceutical manufacturers, regulating agencies, and practitioners. The importance of appropriate medication preparation at all levels of patient care should be emphasized.
As of October 10, approximately 14,000 individuals exposed to recalled MPA were identified, with approximately 97% of these being contacted regarding information of the exposure. 2 As a single agent with a very specific use, the success rate in this recall was high and also speaks to the heroic efforts and collaboration of health departments, CDC, and FDA. However, the subsequent recall of numerous medications in this particular scenario underlines the need for an examination of the recall process and identification of the resources required by health care facilities to manage such incidents effectively. Despite the advent of technology in the medication ordering and administration process, the identification of patients who have received a specific lot number of a specific medication is not easily achieved or possible in all health care areas and continues to be a problem in the documentation of medication procurement and management. It is time to determine what resources are needed to make this a better process.
As we move forward with this national recall and experience its effects, our thoughts are extended to the affected patients. Hopefully, what is learned here will be beneficial for improved patient safety of the future.
